← Back to Clinical Trials
Recruiting NCT03513003

NCT03513003 The Use of a Pacifier to Correct Malocclusions in Young Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03513003
Status Recruiting
Phase
Sponsor University Hospital, Basel, Switzerland
Condition Malocclusion
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2020-06-24
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 2 Years
Max Age 5 Years
Study Type INTERVENTIONAL
Interventions
Functional PacifierStop habit

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2020-06-24 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the study is to investigate the effect of a pacifier (102 Medical Pacifier, Curaprox, Switzerland) on malocclusions like posterior crossbite, anterior open bite, larger overjet and tongue dysfunction in young children.

Eligibility Criteria

Inclusion Criteria: * Children who are sucking the pacifier and / or baby bottle for the last 6 months in use. * Manifesting posterior crossbite in which minium 1 tooth and/or edge to edge in the region deciduous canines and/or deciduous molars, with or without forced bite. AND / OR \- Manifesting anterior open bite in which the overbite has negative values or edge to edge (≤ 0), with or without tongue thrust. Exclusion Criteria: * Children who are thumb- or fingersucking (or sucking other objects) * syndromic or cleft patients * patients with history of cranio-facial trauma, history of temporomandibular joint infection or musculo-skeletal asymmetry (e.g. scoliosis, torticollis) * patients with systematic diseases * patients currently under or after orthodontic Treatment * patients with ankylosed teeth (e.g. after dental trauma).

Contact & Investigator

Central Contact

Carlalberta Verna, DDS, PhD

✉ carlalberta.verna@unibas.ch

📞 0041 061 2672641

Principal Investigator

Carlalberta Verna, DDS, PhD

STUDY CHAIR

University Center for Dental Medicine, Basel, Switzerland

Frequently Asked Questions

Who can join the NCT03513003 clinical trial?

This trial is open to participants of all sexes, aged 2 Years or older, up to 5 Years, studying Malocclusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03513003 currently recruiting?

Yes, NCT03513003 is actively recruiting participants. Contact the research team at carlalberta.verna@unibas.ch for enrollment information.

Where is the NCT03513003 trial being conducted?

This trial is being conducted at Basel, Switzerland.

Who is sponsoring the NCT03513003 clinical trial?

NCT03513003 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Carlalberta Verna, DDS, PhD at University Center for Dental Medicine, Basel, Switzerland. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology